Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12
Increasing evidences show that aberrant subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). However, how subchondral bone formation is activated and the mechanism by which increased subchondral bone turnover promotes cartilage degeneration during OA remains...
Gespeichert in:
Veröffentlicht in: | Bone Research 2019-02, Vol.7 (1), p.5-5, Article 5 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5 |
---|---|
container_issue | 1 |
container_start_page | 5 |
container_title | Bone Research |
container_volume | 7 |
creator | Lin, Chuangxin Liu, Liangliang Zeng, Chun Cui, Zhong-Kai Chen, Yuhui Lai, Pinling Wang, Hong Shao, Yan Zhang, Haiyan Zhang, Rongkai Zhao, Chang Fang, Hang Cai, Daozhang Bai, Xiaochun |
description | Increasing evidences show that aberrant subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). However, how subchondral bone formation is activated and the mechanism by which increased subchondral bone turnover promotes cartilage degeneration during OA remains unclear. Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) pathway is activated in subchondral bone preosteoblasts (Osterix+) from OA patients and mice. Constitutive activation of mTORC1 in preosteoblasts by deletion of the mTORC1 upstream inhibitor, tuberous sclerosis 1, induced aberrant subchondral bone formation, and sclerosis with little-to-no effects on articular cartilage integrity, but accelerated post-traumatic OA development in mice. In contrast, inhibition of mTORC1 in preosteoblasts by disruption of Raptor (mTORC1-specific component) reduced subchondral bone formation and cartilage degeneration, and attenuated post-traumatic OA in mice. Mechanistically, mTORC1 activation promoted preosteoblast expansion and Cxcl12 secretion, which induced subchondral bone remodeling and cartilage degeneration during OA. A Cxcl12-neutralizing antibody reduced cartilage degeneration and alleviated OA in mice. Altogether, these findings demonstrate that mTORC1 activation in subchondral preosteoblasts is not sufficient to induce OA, but can induce aberrant subchondral bone formation and secrete of Cxcl12 to accelerate disease progression following surgical destabilization of the joint. Pharmaceutical inhibition of the pathway presents a promising therapeutic approach for OA treatment.
Arthritis: Activation of mTORC1 promotes osteoarthritis by stimulating bone sclerosis
Mammalian target of rapamycin complex 1 (mTORC1) is a protein complex that controls protein synthesis, and activation of mTORC1 in subchondral preosteoblasts promotes arthritis by stimulating bone sclerosis (abnormal hardening) and secreting C-X-C motif chemokine 12 (CXCL12). Subchondral preosteoblasts are cells that differentiate into bone-forming cells below the cartilage in joints, and CXCL12 is a protein that regulates a wide range of cellular activities. A team headed by Daozhang Cai and Xiaochun Bai of The Third Affiliated Hospital of Southern Medical University, Guangzhou, China investigated mTORC1 activity in subchondral preosteoblasts from osteoarthritis patients and mice. The team found that mTORC1 activation of subchondral preosteoblasts promoted osteoarthritis by stimula |
doi_str_mv | 10.1038/s41413-018-0041-8 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6381187</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2183684626</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-50dc812b3e9cafd5fc65df5f246c2e3a40a4aa962be547f74edb8cfc567817473</originalsourceid><addsrcrecordid>eNp1kctq3DAUhk1paUKaB-imCLrpxqnuljeFYNI2MBAoKXQnZFmeUbClqY4cyAP0vaupJ-kFutLlfOc_-vVX1WuCLwhm6j1wwgmrMVE1xpzU6ll1SnErakkZeX7c8wbjk-oc4A5jTKjirWIvqxOGm5a2TJ5WPy5t9vcm-xhQHNF8e_OlI8gHBEtvdzEMyUyoj8GhfXIRsov9ZCBDOcY5Zgfo16VJeZd89oD6BwTZz8tUNMN2bQU7uRShVE0YEDib3OPA7lu3IfRV9WI0E7jz43pWff14ddt9rjc3n667y01tBVG5FniwitCeudaacRCjlWIYxUi5tNQxw7HhxrSS9k7wZmy4G3plRytko0jDG3ZWfVh190s_u8G6kIs_vU9-NulBR-P135Xgd3ob77VkihB1EHh3FEjx--Ig69mDddNkgosLaEqUEJJKLgr69h_0Li4pFHsHiknFC1coslK2fBAkNz49hmB9yFmvOeuSsz7krFXpefOni6eOx1QLQFcASilsXfo9-v-qPwGcBbY2</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2183684626</pqid></control><display><type>article</type><title>Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12</title><source>PubMed (Medline)</source><source>Springer Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Nature Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Lin, Chuangxin ; Liu, Liangliang ; Zeng, Chun ; Cui, Zhong-Kai ; Chen, Yuhui ; Lai, Pinling ; Wang, Hong ; Shao, Yan ; Zhang, Haiyan ; Zhang, Rongkai ; Zhao, Chang ; Fang, Hang ; Cai, Daozhang ; Bai, Xiaochun</creator><creatorcontrib>Lin, Chuangxin ; Liu, Liangliang ; Zeng, Chun ; Cui, Zhong-Kai ; Chen, Yuhui ; Lai, Pinling ; Wang, Hong ; Shao, Yan ; Zhang, Haiyan ; Zhang, Rongkai ; Zhao, Chang ; Fang, Hang ; Cai, Daozhang ; Bai, Xiaochun</creatorcontrib><description>Increasing evidences show that aberrant subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). However, how subchondral bone formation is activated and the mechanism by which increased subchondral bone turnover promotes cartilage degeneration during OA remains unclear. Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) pathway is activated in subchondral bone preosteoblasts (Osterix+) from OA patients and mice. Constitutive activation of mTORC1 in preosteoblasts by deletion of the mTORC1 upstream inhibitor, tuberous sclerosis 1, induced aberrant subchondral bone formation, and sclerosis with little-to-no effects on articular cartilage integrity, but accelerated post-traumatic OA development in mice. In contrast, inhibition of mTORC1 in preosteoblasts by disruption of Raptor (mTORC1-specific component) reduced subchondral bone formation and cartilage degeneration, and attenuated post-traumatic OA in mice. Mechanistically, mTORC1 activation promoted preosteoblast expansion and Cxcl12 secretion, which induced subchondral bone remodeling and cartilage degeneration during OA. A Cxcl12-neutralizing antibody reduced cartilage degeneration and alleviated OA in mice. Altogether, these findings demonstrate that mTORC1 activation in subchondral preosteoblasts is not sufficient to induce OA, but can induce aberrant subchondral bone formation and secrete of Cxcl12 to accelerate disease progression following surgical destabilization of the joint. Pharmaceutical inhibition of the pathway presents a promising therapeutic approach for OA treatment.
Arthritis: Activation of mTORC1 promotes osteoarthritis by stimulating bone sclerosis
Mammalian target of rapamycin complex 1 (mTORC1) is a protein complex that controls protein synthesis, and activation of mTORC1 in subchondral preosteoblasts promotes arthritis by stimulating bone sclerosis (abnormal hardening) and secreting C-X-C motif chemokine 12 (CXCL12). Subchondral preosteoblasts are cells that differentiate into bone-forming cells below the cartilage in joints, and CXCL12 is a protein that regulates a wide range of cellular activities. A team headed by Daozhang Cai and Xiaochun Bai of The Third Affiliated Hospital of Southern Medical University, Guangzhou, China investigated mTORC1 activity in subchondral preosteoblasts from osteoarthritis patients and mice. The team found that mTORC1 activation of subchondral preosteoblasts promoted osteoarthritis by stimulating abnormal subchondral bone formation and secretion of CXCL12, promoting cartilage degeneration. The authors believe that pharmaceutical inhibition of that pathway offers a promising approach in treating osteoarthritis.</description><identifier>ISSN: 2095-4700</identifier><identifier>ISSN: 2095-6231</identifier><identifier>EISSN: 2095-6231</identifier><identifier>DOI: 10.1038/s41413-018-0041-8</identifier><identifier>PMID: 30792936</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/443/63 ; 692/420 ; Arthritis ; Internal Medicine ; Medicine ; Medicine & Public Health ; Orthopedics</subject><ispartof>Bone Research, 2019-02, Vol.7 (1), p.5-5, Article 5</ispartof><rights>The Author(s) 2019</rights><rights>This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-50dc812b3e9cafd5fc65df5f246c2e3a40a4aa962be547f74edb8cfc567817473</citedby><cites>FETCH-LOGICAL-c518t-50dc812b3e9cafd5fc65df5f246c2e3a40a4aa962be547f74edb8cfc567817473</cites><orcidid>0000-0003-3112-9379</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381187/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381187/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30792936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Chuangxin</creatorcontrib><creatorcontrib>Liu, Liangliang</creatorcontrib><creatorcontrib>Zeng, Chun</creatorcontrib><creatorcontrib>Cui, Zhong-Kai</creatorcontrib><creatorcontrib>Chen, Yuhui</creatorcontrib><creatorcontrib>Lai, Pinling</creatorcontrib><creatorcontrib>Wang, Hong</creatorcontrib><creatorcontrib>Shao, Yan</creatorcontrib><creatorcontrib>Zhang, Haiyan</creatorcontrib><creatorcontrib>Zhang, Rongkai</creatorcontrib><creatorcontrib>Zhao, Chang</creatorcontrib><creatorcontrib>Fang, Hang</creatorcontrib><creatorcontrib>Cai, Daozhang</creatorcontrib><creatorcontrib>Bai, Xiaochun</creatorcontrib><title>Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12</title><title>Bone Research</title><addtitle>Bone Res</addtitle><addtitle>Bone Res</addtitle><description>Increasing evidences show that aberrant subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). However, how subchondral bone formation is activated and the mechanism by which increased subchondral bone turnover promotes cartilage degeneration during OA remains unclear. Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) pathway is activated in subchondral bone preosteoblasts (Osterix+) from OA patients and mice. Constitutive activation of mTORC1 in preosteoblasts by deletion of the mTORC1 upstream inhibitor, tuberous sclerosis 1, induced aberrant subchondral bone formation, and sclerosis with little-to-no effects on articular cartilage integrity, but accelerated post-traumatic OA development in mice. In contrast, inhibition of mTORC1 in preosteoblasts by disruption of Raptor (mTORC1-specific component) reduced subchondral bone formation and cartilage degeneration, and attenuated post-traumatic OA in mice. Mechanistically, mTORC1 activation promoted preosteoblast expansion and Cxcl12 secretion, which induced subchondral bone remodeling and cartilage degeneration during OA. A Cxcl12-neutralizing antibody reduced cartilage degeneration and alleviated OA in mice. Altogether, these findings demonstrate that mTORC1 activation in subchondral preosteoblasts is not sufficient to induce OA, but can induce aberrant subchondral bone formation and secrete of Cxcl12 to accelerate disease progression following surgical destabilization of the joint. Pharmaceutical inhibition of the pathway presents a promising therapeutic approach for OA treatment.
Arthritis: Activation of mTORC1 promotes osteoarthritis by stimulating bone sclerosis
Mammalian target of rapamycin complex 1 (mTORC1) is a protein complex that controls protein synthesis, and activation of mTORC1 in subchondral preosteoblasts promotes arthritis by stimulating bone sclerosis (abnormal hardening) and secreting C-X-C motif chemokine 12 (CXCL12). Subchondral preosteoblasts are cells that differentiate into bone-forming cells below the cartilage in joints, and CXCL12 is a protein that regulates a wide range of cellular activities. A team headed by Daozhang Cai and Xiaochun Bai of The Third Affiliated Hospital of Southern Medical University, Guangzhou, China investigated mTORC1 activity in subchondral preosteoblasts from osteoarthritis patients and mice. The team found that mTORC1 activation of subchondral preosteoblasts promoted osteoarthritis by stimulating abnormal subchondral bone formation and secretion of CXCL12, promoting cartilage degeneration. The authors believe that pharmaceutical inhibition of that pathway offers a promising approach in treating osteoarthritis.</description><subject>631/443/63</subject><subject>692/420</subject><subject>Arthritis</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Orthopedics</subject><issn>2095-4700</issn><issn>2095-6231</issn><issn>2095-6231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kctq3DAUhk1paUKaB-imCLrpxqnuljeFYNI2MBAoKXQnZFmeUbClqY4cyAP0vaupJ-kFutLlfOc_-vVX1WuCLwhm6j1wwgmrMVE1xpzU6ll1SnErakkZeX7c8wbjk-oc4A5jTKjirWIvqxOGm5a2TJ5WPy5t9vcm-xhQHNF8e_OlI8gHBEtvdzEMyUyoj8GhfXIRsov9ZCBDOcY5Zgfo16VJeZd89oD6BwTZz8tUNMN2bQU7uRShVE0YEDib3OPA7lu3IfRV9WI0E7jz43pWff14ddt9rjc3n667y01tBVG5FniwitCeudaacRCjlWIYxUi5tNQxw7HhxrSS9k7wZmy4G3plRytko0jDG3ZWfVh190s_u8G6kIs_vU9-NulBR-P135Xgd3ob77VkihB1EHh3FEjx--Ig69mDddNkgosLaEqUEJJKLgr69h_0Li4pFHsHiknFC1coslK2fBAkNz49hmB9yFmvOeuSsz7krFXpefOni6eOx1QLQFcASilsXfo9-v-qPwGcBbY2</recordid><startdate>20190220</startdate><enddate>20190220</enddate><creator>Lin, Chuangxin</creator><creator>Liu, Liangliang</creator><creator>Zeng, Chun</creator><creator>Cui, Zhong-Kai</creator><creator>Chen, Yuhui</creator><creator>Lai, Pinling</creator><creator>Wang, Hong</creator><creator>Shao, Yan</creator><creator>Zhang, Haiyan</creator><creator>Zhang, Rongkai</creator><creator>Zhao, Chang</creator><creator>Fang, Hang</creator><creator>Cai, Daozhang</creator><creator>Bai, Xiaochun</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3112-9379</orcidid></search><sort><creationdate>20190220</creationdate><title>Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12</title><author>Lin, Chuangxin ; Liu, Liangliang ; Zeng, Chun ; Cui, Zhong-Kai ; Chen, Yuhui ; Lai, Pinling ; Wang, Hong ; Shao, Yan ; Zhang, Haiyan ; Zhang, Rongkai ; Zhao, Chang ; Fang, Hang ; Cai, Daozhang ; Bai, Xiaochun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-50dc812b3e9cafd5fc65df5f246c2e3a40a4aa962be547f74edb8cfc567817473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>631/443/63</topic><topic>692/420</topic><topic>Arthritis</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Orthopedics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Chuangxin</creatorcontrib><creatorcontrib>Liu, Liangliang</creatorcontrib><creatorcontrib>Zeng, Chun</creatorcontrib><creatorcontrib>Cui, Zhong-Kai</creatorcontrib><creatorcontrib>Chen, Yuhui</creatorcontrib><creatorcontrib>Lai, Pinling</creatorcontrib><creatorcontrib>Wang, Hong</creatorcontrib><creatorcontrib>Shao, Yan</creatorcontrib><creatorcontrib>Zhang, Haiyan</creatorcontrib><creatorcontrib>Zhang, Rongkai</creatorcontrib><creatorcontrib>Zhao, Chang</creatorcontrib><creatorcontrib>Fang, Hang</creatorcontrib><creatorcontrib>Cai, Daozhang</creatorcontrib><creatorcontrib>Bai, Xiaochun</creatorcontrib><collection>Springer Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bone Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Chuangxin</au><au>Liu, Liangliang</au><au>Zeng, Chun</au><au>Cui, Zhong-Kai</au><au>Chen, Yuhui</au><au>Lai, Pinling</au><au>Wang, Hong</au><au>Shao, Yan</au><au>Zhang, Haiyan</au><au>Zhang, Rongkai</au><au>Zhao, Chang</au><au>Fang, Hang</au><au>Cai, Daozhang</au><au>Bai, Xiaochun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12</atitle><jtitle>Bone Research</jtitle><stitle>Bone Res</stitle><addtitle>Bone Res</addtitle><date>2019-02-20</date><risdate>2019</risdate><volume>7</volume><issue>1</issue><spage>5</spage><epage>5</epage><pages>5-5</pages><artnum>5</artnum><issn>2095-4700</issn><issn>2095-6231</issn><eissn>2095-6231</eissn><abstract>Increasing evidences show that aberrant subchondral bone remodeling plays an important role in the development of osteoarthritis (OA). However, how subchondral bone formation is activated and the mechanism by which increased subchondral bone turnover promotes cartilage degeneration during OA remains unclear. Here, we show that the mechanistic target of rapamycin complex 1 (mTORC1) pathway is activated in subchondral bone preosteoblasts (Osterix+) from OA patients and mice. Constitutive activation of mTORC1 in preosteoblasts by deletion of the mTORC1 upstream inhibitor, tuberous sclerosis 1, induced aberrant subchondral bone formation, and sclerosis with little-to-no effects on articular cartilage integrity, but accelerated post-traumatic OA development in mice. In contrast, inhibition of mTORC1 in preosteoblasts by disruption of Raptor (mTORC1-specific component) reduced subchondral bone formation and cartilage degeneration, and attenuated post-traumatic OA in mice. Mechanistically, mTORC1 activation promoted preosteoblast expansion and Cxcl12 secretion, which induced subchondral bone remodeling and cartilage degeneration during OA. A Cxcl12-neutralizing antibody reduced cartilage degeneration and alleviated OA in mice. Altogether, these findings demonstrate that mTORC1 activation in subchondral preosteoblasts is not sufficient to induce OA, but can induce aberrant subchondral bone formation and secrete of Cxcl12 to accelerate disease progression following surgical destabilization of the joint. Pharmaceutical inhibition of the pathway presents a promising therapeutic approach for OA treatment.
Arthritis: Activation of mTORC1 promotes osteoarthritis by stimulating bone sclerosis
Mammalian target of rapamycin complex 1 (mTORC1) is a protein complex that controls protein synthesis, and activation of mTORC1 in subchondral preosteoblasts promotes arthritis by stimulating bone sclerosis (abnormal hardening) and secreting C-X-C motif chemokine 12 (CXCL12). Subchondral preosteoblasts are cells that differentiate into bone-forming cells below the cartilage in joints, and CXCL12 is a protein that regulates a wide range of cellular activities. A team headed by Daozhang Cai and Xiaochun Bai of The Third Affiliated Hospital of Southern Medical University, Guangzhou, China investigated mTORC1 activity in subchondral preosteoblasts from osteoarthritis patients and mice. The team found that mTORC1 activation of subchondral preosteoblasts promoted osteoarthritis by stimulating abnormal subchondral bone formation and secretion of CXCL12, promoting cartilage degeneration. The authors believe that pharmaceutical inhibition of that pathway offers a promising approach in treating osteoarthritis.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30792936</pmid><doi>10.1038/s41413-018-0041-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3112-9379</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2095-4700 |
ispartof | Bone Research, 2019-02, Vol.7 (1), p.5-5, Article 5 |
issn | 2095-4700 2095-6231 2095-6231 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6381187 |
source | PubMed (Medline); Springer Open Access; DOAJ Directory of Open Access Journals; Nature Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | 631/443/63 692/420 Arthritis Internal Medicine Medicine Medicine & Public Health Orthopedics |
title | Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T09%3A36%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20mTORC1%20in%20subchondral%20bone%20preosteoblasts%20promotes%20osteoarthritis%20by%20stimulating%20bone%20sclerosis%20and%20secretion%20of%20CXCL12&rft.jtitle=Bone%20Research&rft.au=Lin,%20Chuangxin&rft.date=2019-02-20&rft.volume=7&rft.issue=1&rft.spage=5&rft.epage=5&rft.pages=5-5&rft.artnum=5&rft.issn=2095-4700&rft.eissn=2095-6231&rft_id=info:doi/10.1038/s41413-018-0041-8&rft_dat=%3Cproquest_pubme%3E2183684626%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2183684626&rft_id=info:pmid/30792936&rfr_iscdi=true |